Clinical Trials Logo
  1. Home
  2. Anorexia
  3. NCT02524301

Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study

Anorexia Clinical Trial

Official title:
Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study

Clinical Trial Summary

The place of opioid system in anorexia nervosa (AN) physiopathology is still unclear. Conflicting results were published on cerebral spinal fluid or peripheral levels in anorexia nervosa. However, no data have been reported on opioid cerebral activity. Diprenorphine is a ligand with non-selective binding to opiate receptors µ, κ and δ capable to assess the interaction between endogenous opioids and their receptors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02524301
Study type Interventional
Source Centre Hospitalier Universitaire de Saint Etienne
Contact
Status Completed
Phase N/A
Start date September 2009
Completion date July 29, 2016
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT01501396 - Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite Phase 2
Withdrawn NCT02793102 - Sensory Workshops and Anorexia Nervosa N/A
Active, not recruiting NCT01206335 - Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia Phase 2
Active, not recruiting NCT00488072 - Effects of Mirtazapine on Appetite in Advanced Cancer Patients Phase 2
Withdrawn NCT05039385 - Exercise Program in Patients With Anorexia Nervosa (ESATRAL) N/A
Completed NCT03097874 - Adaptive Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT00031785 - Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer Phase 3
Terminated NCT00535015 - Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer Phase 2
Terminated NCT00558558 - Haelan and Nutrition in Cancer Patients Phase 2
Completed NCT00040885 - Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05) Phase 3
Completed NCT00006799 - Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Phase 3
Active, not recruiting NCT03637816 - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Phase 2/Phase 3
Completed NCT04007900 - Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa N/A
Completed NCT00735540 - Clinical Diagnosis of Teenagers Admitted to Pediatric Departments N/A
Completed NCT00046904 - Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer Phase 3
Completed NCT04803305 - Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia Phase 1
Completed NCT05708404 - Outpatient Treatment of Severe and Enduring Anorexia Nervosa
Completed NCT03283488 - Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. Phase 2
Recruiting NCT05503147 - Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan) Phase 1
Terminated NCT01200602 - Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy Phase 2